Language:

Human Herpesviruses 6, 7 and 8 in Solid Organ Transplant Recipients

American journal of transplantation, 2013-02, Vol.13 (s3), p.67-78 [Peer Reviewed Journal]

Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons ;Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons. ;ISSN: 1600-6135 ;EISSN: 1600-6143 ;DOI: 10.1111/ajt.12008 ;PMID: 23347215

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Human Herpesviruses 6, 7 and 8 in Solid Organ Transplant Recipients
Author: Razonable, R. R.
Subjects: Antiviral Agents - therapeutic use ; Blood & organ donations ; Bone marrow ; Disease ; Herpesviridae ; Herpesviridae Infections - complications ; Herpesviridae Infections - etiology ; Herpesvirus 6, Human - metabolism ; Herpesvirus 7, Human - metabolism ; Herpesvirus 8, Human - metabolism ; Human herpesvirus 6 ; Human herpesvirus 7 ; Human herpesvirus 8 ; Humans ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Kaposi's sarcoma ; Organ Transplantation - adverse effects ; Roseola infantum ; Sarcoma, Kaposi - complications ; Sarcoma, Kaposi - drug therapy ; Sirolimus - therapeutic use ; Transplants & implants
Is Part Of: American journal of transplantation, 2013-02, Vol.13 (s3), p.67-78
Description: Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most common manifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV‐6 and HHV‐7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV‐8 is an oncogenic gamma‐herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV‐8. Reduction in immunosuppression is the first line treatment of HHV‐8 infection. Other alternatives for treatment, especially for HHV‐8 diseases not responsive to immuno‐minimization strategies, are surgery and chemotherapy. Sirolimus has been shown to be a beneficial component for the treatment of Kaposi's sarcoma and the role of antivirals for HHV‐8 infection is being investigated.
Publisher: United States: Wiley Subscription Services, Inc
Language: English
Identifier: ISSN: 1600-6135
EISSN: 1600-6143
DOI: 10.1111/ajt.12008
PMID: 23347215
Source: Geneva Foundation Free Medical Journals at publisher websites
MEDLINE
Alma/SFX Local Collection

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Human Herpesviruses 6, 7 and 8 in Solid Organ Transplant Recipients

Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons ;Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons. ;ISSN: 1600-6135 ;EISSN: 1600-6143 ;DOI: 10.1111/ajt.12008 ;PMID: 23347215

Searching Remote Databases, Please Wait